Q2 saw 11% EPS growth and strong demand, but a sharp payer mix shift from exchange attrition led to higher uninsured volumes and pressured margins. Medicaid supplemental payments and cost controls offset some headwinds, while guidance was revised to reflect these dynamics.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.